A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP)
Stopped The results of the interim analysis showed that the primary endpoint was not met
Conditions
- Proliferative Diabetic Retinopathy
Interventions
- DRUG: CANAKINUMAB (ILARIS®)
Sponsor
PD Dr. med. Stephan Michels
Collaborators
- [object Object]
- [object Object]